MARKET

ESPR

ESPR

Esperion Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.97
+2.93
+9.75%
Closed 17:10 04/02 EDT
OPEN
29.70
PREV CLOSE
30.04
HIGH
33.20
LOW
29.11
VOLUME
912.47K
TURNOVER
--
52 WEEK HIGH
76.98
52 WEEK LOW
24.82
MARKET CAP
907.09M
P/E (TTM)
-8.8662
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ESPR stock price target is 89.27 with a high estimate of 191.00 and a low estimate of 46.00.

EPS

ESPR News

More
  • B of A Securities Initiates Coverage On Esperion Therapeutics with Buy Rating, Announces Price Target to $50
  • Benzinga · 1d ago
  • Oppenheimer sees 26% downside in Intuitive Surgical in premarket action
  • Seeking Alpha - Article · 1d ago
  • The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions
  • Benzinga · 2d ago
  • Esperion launches cholesterol med bempedoic acid in U.S.
  • Seeking Alpha - Article · 3d ago

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About ESPR

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.
More

Webull offers kinds of Esperion Therapeutics Inc stock information, including NASDAQ:ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions.